(2S)-2-[(3S)-3-[(4-bromophenyl)carbamoylamino]-5-methyl-2-oxopyrrolidin-1-yl]pentanamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2S)-2-[(3S)-3-[(4-bromophenyl)carbamoylamino]-5-methyl-2-oxopyrrolidin-1-yl]pentanamide
• 化学式: C₁₇H₂₃BrN₄O₃
• 分子量: 411.3
• InChiKey: KFTARQLIHYEVJD-RYQGGHCKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  105
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS
  申请人：ALLERGAN, INC.

  公开号：EP3078656A1

  公开（公告）日：2016-10-12

  The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.

  本发明涉及 N-脲取代氨基酸的新型酰胺衍生物、其制备工艺、含有它们的药物组合物以及它们作为 N-甲酰肽受体样-1（FPRL-1）受体调节剂的药物用途。
• [EN] USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES<br/>[FR] UTILISATION D'AGONISTES DU RÉCEPTEUR 2 DE PEPTIDE FORMYLE POUR LE TRAITEMENT DE MALADIES DERMATOLOGIQUES
  申请人：ALLERGAN INC

  公开号：WO2014138046A1

  公开（公告）日：2014-09-12

  The present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2).
• [EN] USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES<br/>[FR] UTILISATION D'AGONISTES DU RÉCEPTEUR 2 DE PEPTIDE FORMYLE POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES OCULAIRES
  申请人：ALLERGAN INC

  公开号：WO2014138037A1

  公开（公告）日：2014-09-12

  The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2.